Literature DB >> 26869629

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

Bernhard Reis1, Lori Jukofsky2, Gong Chen2, Giovanni Martinelli3, Hua Zhong2, W Venus So2, Michael J Dickinson4, Mark Drummond5, Sarit Assouline6, Maneja Hashemyan2, Michel Theron1, Steven Blotner2, Je-Hwan Lee7, Margaret Kasner8, Sung-Soo Yoon9, Ruediger Rueger10, Karen Seiter11, Steven A Middleton2, Kevin R Kelly12, Norbert Vey13, Karen Yee14, Gwen Nichols2, Lin-Chi Chen2, William E Pierceall15.   

Abstract

Entities:  

Keywords:  AML; MDM2 antagonism; complementary diagnostics; flow cytometry; idasanutlin

Mesh：

Substances：

Year:  2016        PMID： 26869629      PMCID： PMC5004378          DOI： 10.3324/haematol.2015.139717

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.

Authors:  Hua Zhong; Gong Chen; Lori Jukofsky; David Geho; Sung Won Han; Fabian Birzele; Sabine Bader; Lucia Himmelein; James Cai; Zayed Albertyn; Mark Rothe; Laurent Essioux; Helmut Burtscher; Steven A Middleton; Ruediger Rueger; Lin-Chi Chen; Markus Dangl; Gwen Nichols; William E Pierceall
Journal:  Br J Haematol       Date:  2015-04-08       Impact factor: 6.998

2.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Authors:  Christian Tovar; James Rosinski; Zoran Filipovic; Brian Higgins; Kenneth Kolinsky; Holly Hilton; Xiaolan Zhao; Binh T Vu; Weiguo Qing; Kathryn Packman; Ola Myklebost; David C Heimbrook; Lyubomir T Vassilev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-27       Impact factor: 11.205

Review 3.  Complementary versus companion diagnostics: apples and oranges?

Authors:  Christopher-Paul Milne; Crystal Bryan; Steven Garafalo; Marie McKiernan
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

4.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

5.  Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

Authors:  Isabelle Ray-Coquard; Jean-Yves Blay; Antoine Italiano; Axel Le Cesne; Nicolas Penel; Jianguo Zhi; Florian Heil; Ruediger Rueger; Bradford Graves; Meichun Ding; David Geho; Steven A Middleton; Lyubomir T Vassilev; Gwen L Nichols; Binh Nguyen Bui
Journal:  Lancet Oncol       Date:  2012-10-17       Impact factor: 41.316

Review 6.  Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils.

Authors:  Davide Torti; Livio Trusolino
Journal:  EMBO Mol Med       Date:  2011-09-23       Impact factor: 12.137

7.  A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Authors:  Sébastien Jeay; Swann Gaulis; Stéphane Ferretti; Hans Bitter; Moriko Ito; Thérèse Valat; Masato Murakami; Stephan Ruetz; Daniel A Guthy; Caroline Rynn; Michael R Jensen; Marion Wiesmann; Joerg Kallen; Pascal Furet; François Gessier; Philipp Holzer; Keiichi Masuya; Jens Würthner; Ensar Halilovic; Francesco Hofmann; William R Sellers; Diana Graus Porta
Journal:  Elife       Date:  2015-05-12       Impact factor: 8.140

8.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Authors:  Michael Andreeff; Kevin R Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531
  8 in total
  34 in total

1.  Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.

Authors:  Nicholas J Short; Hind Rafei; Naval Daver; Hyunsoo Hwang; Jing Ning; Jeffrey L Jorgensen; Tapan M Kadia; Courtney D DiNardo; Sa A Wang; Elias Jabbour; Uday Popat; Betul Oran; Jorge Cortes; Marina Konopleva; Musa Yilmaz; Ghayas C Issa; Hagop Kantarjian; Farhad Ravandi
Journal:  Blood Adv       Date:  2020-12-22

Review 2.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

3.  Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.

Authors:  Jo Ishizawa; Kenji Nakamaru; Takahiko Seki; Koichi Tazaki; Kensuke Kojima; Dhruv Chachad; Ran Zhao; Lauren Heese; Wencai Ma; Man Chun John Ma; Courtney DiNardo; Sherry Pierce; Keyur P Patel; Archie Tse; R Eric Davis; Arvind Rao; Michael Andreeff
Journal:  Cancer Res       Date:  2018-02-28       Impact factor: 12.701

Review 4.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Prithviraj Bose; Pankit Vachhani; Jorge E Cortes
Journal:  Curr Treat Options Oncol       Date:  2017-03

Review 5.  The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.

Authors:  Chi-Che Hsieh; Che-Hung Shen
Journal:  Curr Treat Options Oncol       Date:  2019-02-18

6.  Oral idasanutlin in patients with polycythemia vera.

Authors:  John Mascarenhas; Min Lu; Heidi Kosiorek; Elizabeth Virtgaym; Lijuan Xia; Lonette Sandy; Ruben Mesa; Bruce Petersen; Noushin Farnoud; Vesna Najfeld; Raajit Rampal; Amylou Dueck; Ronald Hoffman
Journal:  Blood       Date:  2019-06-05       Impact factor: 22.113

Review 7.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

Review 8.  Finally, An Apoptosis-Targeting Therapeutic for Cancer.

Authors:  Carlo M Croce; John C Reed
Journal:  Cancer Res       Date:  2016-09-30       Impact factor: 12.701

Review 9.  Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Authors:  Minas P Economides; Srdan Verstovsek; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 10.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.